NEW YORK (360Dx) – UK-based Abingdon Health today announced it has completed a £1.1 million ($1.5 million) funding round.

Current shareholders in the firm participated in the financing, which will go toward working capital and the continued extension of Abingdon's lateral flow device products and associated reader systems, including Seralite, the company's rapid test for diagnosing and managing patients with multiple myeloma. Seralite FLC (free light chain) was launched two years ago and provides results within 10 minutes.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.